5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and...
US Senator Elizabeth Warren expresses 'disappointment' in FTC's Amgen decision
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Ho...
November Dogs Of The Dow: 3 Buyable, 4 Watchable
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration....
5 Dow stocks to track during the market correction
The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in each of the past three months.
Amgen gets FDA approval for its inflammatory diseases treatment Wezlana
Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.
U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara
The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara for multiple inflammatory diseases.
Amgen's obesity drug plans, outlook for 2024
Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings i...
Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.
Amgen (AMGN) Q3 Earnings Top Estimates
Amgen (AMGN) came out with quarterly earnings of $4.96 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings of $4.70 per share a year ago.
Amgen stock unmoved by earnings beat
In contrast to market expectations, shares of Amgen, Inc. (NASDAQ:AMGN) remained flat even as the biotechnology giant exceeded third-quarter earnings estimates and once again raised its financial g...
Amgen Boosts Revenue Guidance. But the Stock Trades Lower.
The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.
Amgen's stock jumps premarket after earnings beat and company again raises guidance
Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. The company posted net inco...
Amgen third-quarter sales rise 5%; profit up before charge
Amgen , which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
In the latest trading session, Amgen (AMGN) closed at $276.12, marking a +1.12% move from the previous day.
Related Companies